ProKidney Corp. (NASDAQ: PROK) is -2.93% lower on its value in year-to-date trading and has touched a low of $6.19 and a high of $14.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The PROK stock was last observed hovering at around $9.11 in the last trading session, with the day’s gains setting it 0.5%.
Currently trading at $9.61, the stock is -7.06% and -3.39% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.25 million and changing 5.49% at the moment leaves the stock 0.64% off its SMA200. PROK registered -2.93% loss for a year compared to 6-month gain of -2.24%.
The stock witnessed a -5.78% loss in the last 1 month and extending the period to 3 months gives it a 28.13%, and is -8.04% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 17.17% over the week and 9.46% over the month.
Distance from 52-week low is 55.25% and -31.36% from its 52-week high.
ProKidney Corp. (PROK) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for ProKidney Corp. (PROK) is a “Overweight”. 4 analysts offering their recommendations for the stock have an average rating of 1.80, where 1 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
ProKidney Corp. is expected to release its quarterly report on 03/01/2023.
ProKidney Corp. (PROK) Top Institutional Holders
The shares outstanding are 232.75M, and float is at 35.24M with Short Float at 0.44%.
ProKidney Corp. (PROK) Insider Activity
A total of 13 insider transactions have happened at ProKidney Corp. (PROK) in the last six months, with sales accounting for 2 and purchases happening 11 times. The most recent transaction is an insider purchase by Cowen Aaron, the company’s 10% Owner. SEC filings show that Cowen Aaron bought 7,007 shares of the company’s common stock on Sep 06 at a price of $6.99 per share for a total of $48979.0. Following the purchase, the insider now owns 6.28 million shares.
ProKidney Corp. disclosed in a document filed with the SEC on Aug 31 that Cowen Aaron (10% Owner) bought a total of 3,162 shares of the company’s common stock. The trade occurred on Aug 31 and was made at $8.94 per share for $28258.0. Following the transaction, the insider now directly holds 6.27 million shares of the PROK stock.
Still, SEC filings show that on Aug 30, Cowen Aaron (10% Owner) acquired 706 shares at an average price of $7.49 for $5288.0. The insider now directly holds 6,270,006 shares of ProKidney Corp. (PROK).